TuHURA Biosciences (HURA) Stock Price, News & Analysis

Company Overview

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Key Stats

• Today's Range: $3.90 to $4.19
• 50-Day Range: $1.88 to $4.23
• 52-Week Range: $1.80 to $7.93
• Volume: 149,056 shs
• Average Volume: 264,195 shs
• Market Capitalization: $179.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.67
• Consensus Rating: Buy

HURA Stock Analysis - Frequently Asked Questions

How have HURA shares performed this year?

TuHURA Biosciences' stock was trading at $4.09 at the beginning of the year. Since then, HURA shares have increased by 0.2% and is now trading at $4.10.
View the best growth stocks for 2025 here.

Who are TuHURA Biosciences' major shareholders?

TuHURA Biosciences' top institutional investors include Suncoast Equity Management (0.23%) and Sabal Trust CO (0.09%).

How do I buy shares of TuHURA Biosciences?

Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 4/25/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HURA
• Previous Symbol: NASDAQ:HURA
• CIK: 1498382
• Web: N/A
• Phone: (813) 875-6600
• Fax: 604-608-5685
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.67
• High Stock Price Target: $15.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +208.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,320,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -152.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.54
• Quick Ratio: 1.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.11) per share
• Price / Book: -1.00

Miscellaneous

• Outstanding Shares: 43,680,000
• Free Float: 42,200,000
• Market Cap: $179.09 million
• Optionable: N/A
• Beta: 0.80